Literature DB >> 30798020

Methods to reduce the incidence of false negative trial results in substance use treatment research.

Rachel L Tomko1, Erin A McClure2, Lindsay M Squeglia2, Hayley Treloar Padovano3, Aimee L McRae-Clark2, Nathaniel L Baker4, Matthew J Carpenter2, Kevin M Gray2.   

Abstract

Treatment development and evaluation for substance use disorders are hindered when randomized controlled trials fail to show a treatment effect when one exists. This manuscript provides an overview of addressable methodological factors that may contribute to incorrect trial results. The collection of remote, naturalistic, real-time adherence and substance use data through ambulatory assessment methods in everyday life is presented as a partial solution. Other recommendations related to participant recruitment and selection, ensuring adequate consistency/fidelity and dose of treatment, and rigorously assessing clinical outcomes are discussed. With implementation of eligibility criteria verification, treatment adherence monitoring, and remote assessment of substance use and biomarkers, ambulatory assessment may help improve clinical trial success rates by improving precision, increasing reproducibility, and reducing the impact of methodological issues that may lead to inaccurate trial results.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2019        PMID: 30798020      PMCID: PMC6661207          DOI: 10.1016/j.copsyc.2019.01.009

Source DB:  PubMed          Journal:  Curr Opin Psychol        ISSN: 2352-250X


  56 in total

Review 1.  Lack of herbal supplement characterization in published randomized controlled trials.

Authors:  Peter M Wolsko; David K Solondz; Russell S Phillips; Steven C Schachter; David M Eisenberg
Journal:  Am J Med       Date:  2005-10       Impact factor: 4.965

2.  Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.

Authors:  Ann L Anderson; Shou-Hua Li; Denka Markova; Tyson H Holmes; Nora Chiang; Roberta Kahn; Jan Campbell; Daniel L Dickerson; Gantt P Galloway; William Haning; John D Roache; Christopher Stock; Ahmed M Elkashef
Journal:  Drug Alcohol Depend       Date:  2015-02-07       Impact factor: 4.492

3.  Identifying Drug (Cocaine) Intake Events from Acute Physiological Response in the Presence of Free-living Physical Activity.

Authors:  Syed Monowar Hossain; Amin Ahsan Ali; Mahbubur Rahman; Emre Ertin; David Epstein; Ashley Kennedy; Kenzie Preston; Annie Umbricht; Yixin Chen; Santosh Kumar
Journal:  IPSN       Date:  2014

4.  Predictors of patient cognitive therapy skills and symptom change in two randomized clinical trials: the role of therapist adherence and the therapeutic alliance.

Authors:  Christian A Webb; Robert J Derubeis; Sona Dimidjian; Steven D Hollon; Jay D Amsterdam; Richard C Shelton
Journal:  J Consult Clin Psychol       Date:  2012-04-02

5.  Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials.

Authors:  Dennis M Donovan; George E Bigelow; Gregory S Brigham; Kathleen M Carroll; Allan J Cohen; John G Gardin; John A Hamilton; Marilyn A Huestis; John R Hughes; Robert Lindblad; G Alan Marlatt; Kenzie L Preston; Jeffrey A Selzer; Eugene C Somoza; Paul G Wakim; Elizabeth A Wells
Journal:  Addiction       Date:  2011-07-22       Impact factor: 6.526

Review 6.  Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-06       Impact factor: 3.455

Review 7.  Medication Nonadherence, "Professional Subjects," and Apparent Placebo Responders: Overlapping Challenges for Medications Development.

Authors:  David J McCann; Nancy M Petry; Anders Bresell; Eva Isacsson; Ellis Wilson; Robert C Alexander
Journal:  J Clin Psychopharmacol       Date:  2015-10       Impact factor: 3.153

8.  Cognitive-behavioural therapy for heroin and cocaine use: Ecological momentary assessment of homework simplification and compliance.

Authors:  Jessica Willner-Reid; Damiya Whitaker; David H Epstein; Karran A Phillips; Amber R Pulaski; Kenzie L Preston; Paul Willner
Journal:  Psychol Psychother       Date:  2015-11-04       Impact factor: 3.915

9.  iMStrong: Deployment of a Biosensor System to Detect Cocaine Use.

Authors:  Stephanie Carreiro; Hua Fang; Jianying Zhang; Kelley Wittbold; Shicheng Weng; Rachel Mullins; David Smelson; Edward W Boyer
Journal:  J Med Syst       Date:  2015-10-21       Impact factor: 4.460

Review 10.  Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.

Authors:  Elias M Klemperer; John R Hughes; Shelly Naud
Journal:  Drug Alcohol Depend       Date:  2018-07-24       Impact factor: 4.492

View more
  4 in total

1.  Quantification of Smoking Characteristics Using Smartwatch Technology: Pilot Feasibility Study of New Technology.

Authors:  Casey Anne Cole; Shannon Powers; Rachel L Tomko; Brett Froeliger; Homayoun Valafar
Journal:  JMIR Form Res       Date:  2021-02-05

Review 2.  Alcohol and Cannabis Use and the Developing Brain.

Authors:  Briana Lees; Jennifer Debenham; Lindsay M Squeglia
Journal:  Alcohol Res       Date:  2021-09-09

Review 3.  Digitally Enabled, Patient-Centric Clinical Trials: Shifting the Drug Development Paradigm.

Authors:  Marissa F Dockendorf; Bryan J Hansen; Kevin P Bateman; Matthew Moyer; Jyoti K Shah; Lisa A Shipley
Journal:  Clin Transl Sci       Date:  2020-11-30       Impact factor: 4.689

Review 4.  Remote Methods for Conducting Tobacco-Focused Clinical Trials.

Authors:  Jennifer Dahne; Rachel L Tomko; Erin A McClure; Jihad S Obeid; Matthew J Carpenter
Journal:  Nicotine Tob Res       Date:  2020-12-12       Impact factor: 4.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.